Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
LARYNGEAL MUCORMYCOSIS IN AN UNCONTROLLED DIABETIC PATIENT: A CASE REPORT.
J Ayub Med Coll Abbottabad
December 2024
Department of ENT, Shaikh Zayed Hospital, Lahore, Department of ENT, Ayub Medical College, Abbottabad-Pakistan.
Background: With rising conditions in immunocompromised states, the world is facing the challenge of fungal infections with mucormycosis which was rare previously. With the rise in diabetic patients, COVID-19-related immunosuppression, and steroid use, along with an increasing number of transplant and chemotherapy patients, there has been a notable surge in mucorales infections. Although patients with rhino-orbit-cerebral mucormycosis are the most common type of pulmonary rare ones.
View Article and Find Full Text PDFComplete central airway obstruction from aggressive mucormycosis in a patient with acute myeloid leukaemia.
BMJ Case Rep
November 2024
Interventional Pulmonology, Oncomedicine division, Banner MD Anderson Cancer Center, Gilbert, Arizona, USA
A woman in her 30s with type 2 diabetes and morbid obesity presented with flu-like symptoms, persistent cough and mild dyspnoea, unresponsive to pneumonia treatment. Diagnosed with acute myeloid leukaemia, she was started on induction chemotherapy. Despite prophylactic antifungal and antibacterial therapy, she developed a fever, a right upper lobe opacity and a complete airway obstruction by a large endobronchial mass in the right main stem.
View Article and Find Full Text PDFEpidemiological Trends of Mucormycosis in Europe, Comparison with Other Continents.
Mycopathologia
November 2024
Fourth Department of Internal Medicine, General University Hospital "Attikon", National and Kapodistrian University of Athens, 12462, Athens, Greece.
Article Synopsis
- * The incidence in developed countries is relatively low (0.06 to 0.3 cases per 100,000), but in India, it spikes to about 14 cases per 100,000, making it significantly more prevalent there than in Europe, where rates range from 0.04 to 0.12.
- * Diabetes mellitus is the most common risk factor globally for mucormycosis, with varying patterns; in Europe, hematological cancers are more prevalent, while the disease often appears in patients
Potential activity of nanomaterials to combat SARS-CoV-2 and mucormycosis coinfection.
Expert Rev Anti Infect Ther
December 2024
Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Article Synopsis
- * There is a growing interest in the use of antifungal nanomaterials as a potential treatment alternative, as they may improve the management of COVID-19-related fungal infections like mucormycosis.
- * Recent developments in nanomaterials offer promise, but more research is necessary to effectively utilize these therapies against mucormycosis, especially when it occurs alongside viral infections.
Invasive fungal infections in patients with acute leukemia: A retrospective cohort study at a tertiary-care hospital.
Medicine (Baltimore)
October 2024
Hacettepe University Faculty of Medicine, Department of Chest Diseases, Ankara, Turkey.
Invasive fungal infection (IFI) is an important cause of morbidity and mortality in acute leukemia patients. In the past few decades, the incidence of IFI has dramatically increased. Nevertheless, the management of IFI has become more complicated owing to changes in the epidemiology of fungal diseases and therapeutic regimens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!